Harrow Health, Inc. (HROW)
USD 25.84
(3.34%)
USD 25.84
(3.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 580 Thousand USD | 133.22% |
| 2022 | -1.74 Million USD | -514.79% |
| 2021 | -284 Thousand USD | 82.6% |
| 2020 | -1.63 Million USD | -224.45% |
| 2019 | -503 Thousand USD | 90.36% |
| 2018 | -5.21 Million USD | 57.11% |
| 2017 | -12.16 Million USD | 23.42% |
| 2016 | -15.88 Million USD | -7.15% |
| 2015 | -14.82 Million USD | -46.08% |
| 2014 | -10.14 Million USD | -32.0% |
| 2013 | -7.68 Million USD | -83.95% |
| 2012 | -4.17 Million USD | -344.93% |
| 2011 | -939.22 Thousand USD | 62.47% |
| 2010 | -2.5 Million USD | 45.17% |
| 2009 | -4.56 Million USD | -21.83% |
| 2008 | -3.74 Million USD | -31.02% |
| 2007 | -2.85 Million USD | -6088.35% |
| 2006 | -46.2 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.53 Million USD | 122.08% |
| 2024 Q1 | -6.92 Million USD | -54.13% |
| 2023 Q2 | 2.35 Million USD | 260.44% |
| 2023 Q1 | -1.46 Million USD | 17.55% |
| 2023 Q3 | 1.74 Million USD | -25.85% |
| 2023 FY | 580 Thousand USD | 133.22% |
| 2023 Q4 | -4.49 Million USD | -357.74% |
| 2022 Q1 | -785 Thousand USD | 55.27% |
| 2022 FY | -1.74 Million USD | -514.79% |
| 2022 Q4 | -1.77 Million USD | -1791.49% |
| 2022 Q3 | -94 Thousand USD | -105.56% |
| 2022 Q2 | 1.69 Million USD | 315.29% |
| 2021 Q3 | -3.71 Million USD | -189.16% |
| 2021 FY | -284 Thousand USD | 82.6% |
| 2021 Q1 | 2.91 Million USD | 11.08% |
| 2021 Q2 | 4.16 Million USD | 42.92% |
| 2021 Q4 | -1.75 Million USD | 52.78% |
| 2020 Q1 | -628 Thousand USD | -168.41% |
| 2020 Q3 | 1.59 Million USD | 149.75% |
| 2020 FY | -1.63 Million USD | -224.45% |
| 2020 Q2 | -3.21 Million USD | -411.15% |
| 2020 Q4 | 2.62 Million USD | 64.43% |
| 2019 FY | -503 Thousand USD | 90.36% |
| 2019 Q1 | -556 Thousand USD | 74.29% |
| 2019 Q2 | -767 Thousand USD | -37.95% |
| 2019 Q3 | -4.39 Million USD | -473.4% |
| 2019 Q4 | 918 Thousand USD | 120.87% |
| 2018 Q2 | -624 Thousand USD | 64.96% |
| 2018 Q3 | -649 Thousand USD | -4.01% |
| 2018 Q4 | -2.16 Million USD | -233.28% |
| 2018 Q1 | -1.78 Million USD | 17.2% |
| 2018 FY | -5.21 Million USD | 57.11% |
| 2017 Q4 | -2.15 Million USD | 22.18% |
| 2017 Q3 | -2.76 Million USD | 8.39% |
| 2017 Q2 | -3.01 Million USD | 28.69% |
| 2017 FY | -12.16 Million USD | 23.42% |
| 2017 Q1 | -4.23 Million USD | -20.61% |
| 2016 Q4 | -3.5 Million USD | 23.94% |
| 2016 Q2 | -4 Million USD | -6.77% |
| 2016 Q3 | -4.61 Million USD | -15.07% |
| 2016 FY | -15.88 Million USD | -7.15% |
| 2016 Q1 | -3.75 Million USD | 20.04% |
| 2015 Q3 | -3.52 Million USD | -1.38% |
| 2015 Q4 | -4.69 Million USD | -33.04% |
| 2015 FY | -14.82 Million USD | -46.08% |
| 2015 Q1 | -3.11 Million USD | -13.35% |
| 2015 Q2 | -3.48 Million USD | -11.68% |
| 2014 Q2 | -2.6 Million USD | -11.45% |
| 2014 FY | -10.14 Million USD | -32.0% |
| 2014 Q4 | -2.74 Million USD | -11.86% |
| 2014 Q3 | -2.45 Million USD | 5.55% |
| 2014 Q1 | -2.33 Million USD | -23.35% |
| 2013 Q4 | -1.89 Million USD | 9.4% |
| 2013 FY | -7.68 Million USD | -83.95% |
| 2013 Q1 | -1.47 Million USD | -0.95% |
| 2013 Q2 | -2.23 Million USD | -51.51% |
| 2013 Q3 | -2.08 Million USD | 6.32% |
| 2012 Q3 | -1.25 Million USD | -11.78% |
| 2012 Q2 | -1.11 Million USD | -217.77% |
| 2012 FY | -4.17 Million USD | -344.93% |
| 2012 Q1 | -351.91 Thousand USD | -12.38% |
| 2012 Q4 | -1.45 Million USD | -16.69% |
| 2011 Q2 | -145.76 Thousand USD | 64.78% |
| 2011 Q1 | -413.82 Thousand USD | -1.61% |
| 2011 Q3 | -66.49 Thousand USD | 54.38% |
| 2011 Q4 | -313.14 Thousand USD | -370.92% |
| 2011 FY | -939.22 Thousand USD | 62.47% |
| 2010 FY | -2.5 Million USD | 45.17% |
| 2010 Q3 | -727.77 Thousand USD | -46.5% |
| 2010 Q2 | -496.76 Thousand USD | 42.95% |
| 2010 Q1 | -870.74 Thousand USD | -12.13% |
| 2010 Q4 | -407.28 Thousand USD | 44.04% |
| 2009 FY | -4.56 Million USD | -21.83% |
| 2009 Q1 | -1.62 Million USD | -68.82% |
| 2009 Q4 | -776.52 Thousand USD | 16.43% |
| 2009 Q3 | -929.23 Thousand USD | 24.47% |
| 2009 Q2 | -1.23 Million USD | 24.43% |
| 2008 Q4 | -964.35 Thousand USD | -215.54% |
| 2008 Q1 | -666.95 Thousand USD | 57.08% |
| 2008 FY | -3.74 Million USD | -31.02% |
| 2008 Q3 | 834.67 Thousand USD | 165.19% |
| 2008 Q2 | -1.28 Million USD | -91.98% |
| 2007 FY | -2.85 Million USD | -6088.35% |
| 2007 Q2 | -1109.00 USD | 41.54% |
| 2007 Q3 | 969.14 Thousand USD | 87489.0% |
| 2007 Q4 | -1.55 Million USD | -260.33% |
| 2007 Q1 | -1897.00 USD | 34.65% |
| 2006 Q4 | -2903.00 USD | 62.46% |
| 2006 FY | -46.2 Thousand USD | 0.0% |
| 2006 Q3 | -7733.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 98.765% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 103.841% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 99.653% |
| Cosmos Health Inc. | -21.83 Million USD | 102.657% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 102.893% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 100.373% |
| Cronos Group Inc. | -81.37 Million USD | 100.713% |
| Incannex Healthcare Limited | -30.04 Million USD | 101.931% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 101.481% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 93.784% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 112.245% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 112.12% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 112.12% |
| SCYNEXIS, Inc. | 72.66 Million USD | 99.202% |
| Safety Shot Inc | -12.18 Million USD | 104.76% |
| Theratechnologies Inc. | -10.62 Million USD | 105.458% |
| Alpha Teknova, Inc. | -35.56 Million USD | 101.631% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 116.446% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 99.338% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 112.338% |
| Dynavax Technologies Corporation | -37.02 Million USD | 101.566% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 99.723% |
| Radius Health, Inc. | -3.92 Million USD | 114.777% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 123.06% |
| Alvotech | -354.86 Million USD | 100.163% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 100.364% |
| SIGA Technologies, Inc. | 83.62 Million USD | 99.306% |
| Shineco, Inc. | -17.06 Million USD | 103.399% |
| Silver Spike Investment Corp. | 7.34 Million USD | 92.098% |
| Journey Medical Corporation | -2.07 Million USD | 127.979% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 104.259% |
| Embecta Corp. | 221.5 Million USD | 99.738% |
| Procaps Group, S.A. | 38.97 Million USD | 98.512% |
| Biofrontera Inc. | -22.67 Million USD | 102.558% |
| DURECT Corporation | -36.88 Million USD | 101.572% |
| PainReform Ltd. | -9.58 Million USD | 106.052% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 111.008% |
| OptiNose, Inc. | -22.74 Million USD | 102.55% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 95.408% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 95.369% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 109.339% |
| ProPhase Labs, Inc. | -21.61 Million USD | 102.684% |
| Phibro Animal Health Corporation | 53.31 Million USD | 98.912% |
| Procaps Group S.A. | 52.32 Million USD | 98.892% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 106.805% |
| Viatris Inc. | 766.2 Million USD | 99.924% |
| Rockwell Medical, Inc. | -6.67 Million USD | 108.696% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 111.039% |
| Tilray Brands, Inc. | -174.74 Million USD | 100.332% |
| PetIQ, Inc. | 60.01 Million USD | 99.034% |
| Talphera, Inc. | -16.88 Million USD | 103.434% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 99.769% |
| Alimera Sciences, Inc. | -1.47 Million USD | 139.429% |
| Assertio Holdings, Inc. | -243.53 Million USD | 100.238% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 109.843% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 100.421% |
| Hempacco Co., Inc. | -8.81 Million USD | 106.582% |
| Alvotech | -354.86 Million USD | 100.163% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 99.841% |
| Kamada Ltd. | 10.06 Million USD | 94.237% |
| Currenc Group, Inc. | -6.64 Million USD | 108.727% |
| Indivior PLC | -4 Million USD | 114.5% |
| Evoke Pharma, Inc. | -7.43 Million USD | 107.805% |
| Flora Growth Corp. | -50.35 Million USD | 101.152% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 102.893% |
| Evolus, Inc. | -49.23 Million USD | 101.178% |
| HUTCHMED (China) Limited | 18.37 Million USD | 96.844% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 99.706% |
| Akanda Corp. | -10.05 Million USD | 105.77% |